Moldova is an early stage clinical research market in Eastern Europe with long term regional potential.
With a population of 2.6 million, around 160 trials listed on ClinicalTrials.gov and a medical system centered around Chișinău, Moldova is still developing its role in international clinical research.
The country’s strongest research opportunities are across cardiometabolic health, oncology, infectious disease research, endocrinology, neurology, respiratory health and hematology.
For sponsors, Moldova is best viewed as part of a broader Central and Eastern European study strategy. Its value comes from early site relationships, competitive operating costs, motivated investigators and access to patient groups that are less represented in larger Western European trial markets.
The clearest signal is Moldova’s cardiometabolic research relevance. For sponsors planning regional studies, the country can offer focused site access and meaningful recruitment potential within a developing European research ecosystem.